A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Public ClinicalTrials.gov record NCT04913285. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
Study identification
- NCT ID
- NCT04913285
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pierre Fabre Medicament
- Industry
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Interventions
- KIN-2787 Drug
- KIN-2787 and binimetinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 3, 2021
- Primary completion
- Nov 29, 2028
- Completion
- Mar 29, 2029
- Last update posted
- Apr 26, 2026
2021 – 2029
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic | Los Angeles | California | 90025-6602 | — |
| UCLA | Los Angeles | California | 90095 | — |
| University of California San Diego, Moores Cancer Center | San Diego | California | 92093 | — |
| University of California San Francisco | San Francisco | California | 94143-2205 | — |
| Stanford Cancer Center | Stanford | California | 94305 | — |
| Sarah Cannon Research Institute Denver | Denver | Colorado | 80218-1238 | — |
| Mayo Clinic - Florida | Jacksonville | Florida | 32224 | — |
| Sarah Cannon Research Institute - Florida Cancer Specialists | Orlando | Florida | 32827 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Atlantic Health | Morristown | New Jersey | 07960 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| NYU Langone | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Sarah Cannon Research Institute-Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| MD Anderson | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04913285, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2026 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04913285 live on ClinicalTrials.gov.